The antibody drug conjugate, belantamab-mafodotin, in the treatment of multiple myeloma: A comprehensive review

Multiple myeloma (MM) remains largely incurable, with relapses due to therapy resistance. This review highlights belantamab mafodotin, the first antibody-drug conjugate targeting BCMA, which is predominantly expressed in malignant plasma cells. By disrupting microtubules and signaling pathways, it shows promise in treating relapsed/refractory MM, as evidenced by pre-clinical and clinical DREAMM studies.